Oncimmune Holdings PLC Director/PDMR Shareholding (3806W)
11 Dicembre 2023 - 4:12PM
UK Regulatory
TIDMONC
RNS Number : 3806W
Oncimmune Holdings PLC
11 December 2023
11 DECEMBER 2023
Oncimmune Holdings plc
("Oncimmune" or the "Company")
Director/PDMR Dealing
Oncimmune Holdings plc (AIM: ONC.L), a leading autoantibody
profiling company to the pharmaceutical and biotechnology industry,
has been notified that on 8 December 2023, Mr Martin Gouldstone,
PDMR and Chief Executive Officer, purchased 36,023 ordinary shares
of GBP0.01 each in the Company ("Ordinary Shares") at a price of
GBP0.2725 per share.
Following this transaction Mr Gouldstone has a total interest in
the Company of 36,023 Ordinary Shares, representing approximately
0.05 per cent of the Company's issued share capital of 74,142,147.
In addition, Mr Gouldstone holds options over 589,971 Ordinary
Shares, representing approximately 0.8 per cent of the Company's
issued share capital.
This announcement, including the notification below, is made in
accordance with the requirements of Article 19 of the UK Market
Abuse Regulation.
Notification and public disclosure of transactions by person
discharging managerial responsibilities and persons closely
associated with them.
Details of the person discharging managerial responsibilities
1 / person closely associated
a) Name Mr Martin Gouldstone
-------------------------------------- --------------------------------------
Reason for the notification
2
------------------------------------------------------------------------------
a) Position/status Chief Executive Officer
-------------------------------------- --------------------------------------
b) Initial notification Initial Notification
/Amendment
-------------------------------------- --------------------------------------
Details of the issuer, emission allowance market participant,
3 auction platform, auctioneer or auction monitor
------------------------------------------------------------------------------
a) Name Oncimmune Holdings plc
-------------------------------------- --------------------------------------
b) LEI 213800HCYIWT6YPI1I02
-------------------------------------- --------------------------------------
Details of the transaction(s): section to be repeated
4 for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
------------------------------------------------------------------------------
a) Description of the Ordinary Shares of GBP0.01 each
financial instrument,
type of instrument
Identification code ISIN: GB00BYQ94H38
b) Nature of the transaction Purchase of Ordinary Shares
-------------------------------------- --------------------------------------
c) Price(s) and volume(s)
----------------- ----------------
Price(s) Volume(s)
----------------- ----------------
GBP0.2725 36,023
------------------------------------------------------------- ----------------
d) Aggregated information N/A - single transaction
- Aggregated volume
- Price
e) Date of the transaction 8 December 2023
-------------------------------------- --------------------------------------
f) Place of the transaction London Stock Exchange, AIMX
-------------------------------------- --------------------------------------
For further information:
contact@oncimmune.co.uk
Singer Capital Markets (Nominated Adviser and Broker)
Phil Davies, Harry Gooden, James Fischer
+44 (0)20 7496 3000
Zeus (Joint Broker)
Dominic King, Victoria Ayton, Dan Bate
+44 (0)20 3829 5000
+44 (0)20 3727 1000
About Oncimmune
Oncimmune is a global leader in immune biomarkers and
immunodiagnostics, offering autoantibody biomarker profiling in
immunooncology, autoimmune and infectious diseases. Through its
ImmunoINSIGHTS(TM) technology platform, the Company provides
insights and analytics to discover and validate novel biomarkers,
improve treatment responses and adverse event (irAE) prediction,
patient screening and diagnostic accuracy.
Oncimmune is headquartered in the UK, with its discovery and
development facility based in Dortmund, Germany and a business
development team based in the US and Europe.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHEFLFFXLLFFBB
(END) Dow Jones Newswires
December 11, 2023 10:12 ET (15:12 GMT)
Grafico Azioni Oncimmune (LSE:ONC)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Oncimmune (LSE:ONC)
Storico
Da Apr 2023 a Apr 2024